RegenETP, Inc. (RGTPQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RegenETP, Inc. (RGTPQ) trades at $0.16. RegenETP, Inc. is a clinical-stage biotechnology company focused on regenerative tissue products and biomaterials. Their lead product, SkinTE, aims to address skin repair and reconstruction across various medical applications. Market cap: $1.18M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for RGTPQ: RGTPQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RGTPQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RGTPQ: 2/2 scored disciplines lean bearish. Dominant signal: Jim Simons bullish.
How is this calculated? →RegenETP, Inc. (RGTPQ) Healthcare & Pipeline Overview
RegenETP, Inc., operating in the regenerative medicine sector, develops and commercializes tissue products like SkinTE for skin repair and reconstruction. The company's focus on regenerative medicine and contract services positions it within a competitive landscape of biotechnology firms, with a market capitalization of $1.18M.
What Is the Investment Thesis for RGTPQ?
RegenETP, Inc. presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. The company's SkinTE product targets a significant market need in skin repair and reconstruction. Key value drivers include successful clinical trials for SkinTE and subsequent regulatory approvals. Growth catalysts include the development and commercialization of SkinTE Cryo and the point-of-care device, potentially expanding the product's reach and application. However, the company faces significant risks, including the need for additional funding, competition from established players, and the uncertainty inherent in clinical-stage biotechnology development. With a beta of 2.91, the stock demonstrates high volatility.
Based on FMP financials and quantitative analysis
RGTPQ Key Highlights
RegenETP operates in the regenerative medicine sector, a rapidly growing field within biotechnology.
- The company's lead product, SkinTE, targets a significant market need in skin repair and reconstruction.
- RegenETP is developing SkinTE Cryo and a point-of-care device to expand the product's reach and application.
- The company operates through two segments: Regenerative Medicine Products and Contract Services.
- RegenETP changed its name from PolarityTE, Inc. in August 2023, reflecting a strategic shift.
Who Are RGTPQ's Competitors?
RGTPQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGTPQ's Key Strengths?
Proprietary SkinTE technology
- Focus on regenerative medicine
- Potential for innovative products
- Contract service revenue stream
What Are RGTPQ's Weaknesses?
Clinical-stage company with limited revenue
- Dependence on SkinTE for growth
- Requires significant funding for R&D
- OTC market listing
What Could Drive RGTPQ Stock Higher?
Clinical trial results for SkinTE.
- Regulatory approvals for SkinTE Cryo.
- Launch of SkinTE point-of-care device.
- Expansion of SkinTE applications.
- Strategic partnerships and collaborations.
What Are the Key Risks for RGTPQ?
Clinical trial failures.
- Regulatory approval delays.
- Competition from established players.
- Need for additional funding.
- OTC market listing and associated risks.
What Are the Growth Opportunities for RGTPQ?
- Expansion of SkinTE Applications: RegenETP has the opportunity to expand the applications of SkinTE beyond its current indications. This could involve targeting new types of wounds, burns, or surgical reconstruction procedures. Timeline: Ongoing, with continuous research and development efforts.
- Commercialization of SkinTE Cryo: The development and commercialization of SkinTE Cryo, which allows for multiple deployments from a single harvest, represents a significant growth opportunity. This could improve the cost-effectiveness and convenience of SkinTE, potentially increasing its adoption. Timeline: Development and regulatory approval are ongoing.
- Development of Point-of-Care Device: The development of a SkinTE point-of-care device would enable immediate processing and deployment of SkinTE at the point of care. This could streamline the treatment process and improve patient outcomes. The market for point-of-care diagnostics and therapeutics is growing rapidly. Timeline: Development and regulatory approval are ongoing.
- Strategic Partnerships and Collaborations: RegenETP can pursue strategic partnerships and collaborations with other companies in the healthcare industry to expand its reach and access new markets. This could involve partnering with hospitals, clinics, or pharmaceutical companies. Timeline: Ongoing, with continuous business development efforts.
- Geographic Expansion: RegenETP has the opportunity to expand its operations beyond the United States and into international markets. This could involve seeking regulatory approvals in other countries and establishing distribution networks. The global market for regenerative medicine is growing rapidly, particularly in Asia and Europe. Timeline: Dependent on regulatory approvals and market conditions.
What Are RGTPQ's Competitive Advantages?
- Proprietary SkinTE technology.
- Intellectual property protection for its products.
- Potential first-mover advantage in certain market segments.
- Expertise in regenerative medicine and tissue engineering.
What Does RGTPQ Do?
RegenETP, Inc., formerly known as PolarityTE, Inc., is a clinical-stage biotechnology company headquartered in Salt Lake City, Utah. Founded with the vision of transforming regenerative medicine, the company develops and commercializes a range of regenerative tissue products and biomaterials. Its primary focus is on addressing unmet needs in medicine, biomedical engineering, and material sciences. The company operates through two segments: Regenerative Medicine Products and Contract Services. RegenETP's flagship product, SkinTE, is a tissue-based product designed for the repair, reconstruction, replacement, and supplementation of skin in patients. SkinTE is intended for treating acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The company is also developing SkinTE Cryo, which allows for multiple deployments from a single harvest through cryopreservation. Additionally, they are working on a SkinTE point-of-care device to enable immediate processing and deployment of SkinTE at the point of care. The company also provides contract research services. RegenETP aims to establish itself as a key player in the regenerative medicine market through continued innovation and product development.
What Products and Services Does RGTPQ Offer?
- Develop and commercialize regenerative tissue products.
- Offer SkinTE for skin repair and reconstruction.
- Develop SkinTE Cryo for multiple deployments from one harvest.
- Create SkinTE point-of-care device for immediate processing.
- Provide contract research services.
- Focus on medicine, biomedical engineering, and material sciences.
How Does RGTPQ Make Money?
- Sales of SkinTE and other regenerative medicine products.
- Revenue from contract research services.
- Potential licensing agreements for its technologies.
- Future revenue from SkinTE Cryo and point-of-care device.
What Industry Does RGTPQ Operate In?
RegenETP operates within the regenerative medicine industry, a dynamic sector focused on developing therapies to repair or replace damaged tissues and organs. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. The competitive landscape includes established players and emerging companies developing innovative regenerative medicine products. RegenETP's focus on skin repair and reconstruction positions it within a specific niche of this broader market. The company competes with firms offering alternative wound care solutions and other regenerative therapies.
Who Are RGTPQ's Key Customers?
- Hospitals and clinics.
- Burn centers.
- Plastic surgeons.
- Patients with acute or chronic wounds.
Company Profile
RegenETP, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Richard Hague. RGTPQ has traded publicly since 1999.
RGTPQ Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in RegenETP's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to energy solutions.
- Recent partnerships announced in the renewable sector have generated excitement, positioning RegenETP as a key player in a growing market.
- Social media buzz indicates increasing interest from retail investors, reflecting a broader trend towards sustainable investments.
Bear Case
- Concerns about regulatory challenges in the renewable energy sector have surfaced, potentially impacting RegenETP's operations.
- Recent earnings reports have raised questions about the company's profitability, causing some investors to reevaluate their positions.
- Market sentiment remains cautious due to broader economic uncertainties, which could dampen enthusiasm for stocks like RegenETP.
- Negative commentary from influential analysts points to potential hurdles in scaling operations, leading to skepticism among some investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RGTPQ Latest News
No recent news available for RGTPQ.
RGTPQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGTPQ.
Price Targets
Wall Street price target analysis for RGTPQ.
RGTPQ MoonshotScore
What does this score mean?
The MoonshotScore rates RGTPQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Richard Hague
CEO
Richard Hague serves as the CEO of RegenETP, Inc. His background includes extensive experience in managing and leading teams within the biotechnology sector. He is responsible for overseeing the company's strategic direction, operations, and financial performance. Hague's leadership is focused on advancing the development and commercialization of RegenETP's regenerative medicine products.
Track Record: Since assuming the role of CEO, Richard Hague has focused on streamlining operations and advancing the clinical development of SkinTE. Key milestones under his leadership include the progression of SkinTE Cryo and the point-of-care device. His strategic decisions aim to position RegenETP as a key player in the regenerative medicine market.
RGTPQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RegenETP may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. This tier is generally associated with higher risk and greater potential for volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other tier status.
- Lower trading volume and liquidity compared to major exchanges.
- Increased price volatility.
- Higher risk of fraud or manipulation.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Review the company's regulatory filings and legal history.
- Consult with a financial advisor before investing.
- Check for any news or red flags about the company.
- Development of SkinTE and other regenerative medicine products.
- Focus on addressing unmet needs in healthcare.
- Experienced management team led by Richard Hague.
- Operations in the regenerative medicine sector.
RGTPQ Healthcare Stock FAQ
What does RegenETP, Inc. do?
RegenETP, Inc. is a clinical-stage biotechnology company focused on developing and commercializing regenerative tissue products and biomaterials. Their primary product, SkinTE, is designed for skin repair, reconstruction, and supplementation in patients with acute or chronic wounds, burns, or surgical reconstruction needs. The company also provides contract research services. RegenETP aims to establish itself as a key player in the regenerative medicine market through continued innovation and product development.
What are the main risks for RGTPQ?
RegenETP faces several key risks, including the uncertainty of clinical trial outcomes for SkinTE and its related products. Regulatory approval delays or failures could significantly impact the company's prospects. Competition from established players in the wound care and regenerative medicine markets poses a threat. The company's need for additional funding and its OTC market listing also present significant risks. Investors should carefully consider these factors before investing.
How does RegenETP, Inc. navigate regulatory approval processes?
RegenETP, Inc., as a clinical-stage biotechnology company, must navigate complex regulatory pathways to gain approval for its products, particularly SkinTE. The company's strategy likely involves close collaboration with regulatory agencies like the FDA, adherence to rigorous clinical trial protocols, and comprehensive data submission.
How does RegenETP, Inc. manage patent expiration risks?
As a biotechnology company, RegenETP, Inc. faces the risk of patent expirations on its key technologies, including those related to SkinTE. To mitigate this risk, the company likely employs strategies such as filing new patent applications for novel innovations, developing proprietary manufacturing processes, and exploring alternative formulations or delivery methods. The strength and breadth of RegenETP, Inc.'s intellectual property portfolio are critical to its long-term competitive advantage.
What are the key factors to evaluate for RGTPQ?
Evaluate RGTPQ on fundamentals, analyst consensus, and risk factors. RegenETP, Inc. presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. Not financial advice.
How frequently does RGTPQ data refresh on this page?
RGTPQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RGTPQ's recent stock price performance?
RegenETP, Inc. (RGTPQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SkinTE technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGTPQ overvalued or undervalued right now?
RegenETP, Inc. (RGTPQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed company.
- AI analysis pending for RGTPQ.